Why the study?
Assessing endothelial dysfunction and arterial stiffness is not straightforward, and new biomarkers are required to stratify heterogeneous CVD risk in diabetes. This study examined whether MCP-1 is associated with endothelial function and large artery stiffness independently of traditional CVD risk factors in patients with and without T2DM.
Cross-Sectional (n=738)
Yes
Answers are grounded in this paper and cite their sources.
Higher MCP-1 levels are independently associated with reduced endothelium-dependent and endothelium-independent microvascular vasodilator capacity, but not large artery stiffness, in individuals with and without type 2 diabetes.
BACKGROUND: Endothelial dysfunction and arterial stiffness have been shown to be associated with cardiovascular disease (CVD) outcomes but assessment of these is not straightforward. CVD risk in diabetes shows heterogeneity and new biomarkers are required to stratify CVD risk in these patients. The aim of this study was to determine the association between MCP-1 and measures of endothelial function and large artery stiffness, independently of traditional CVD risk factors, in patients with and without Type 2 diabetes mellitus (T2DM). METHODS: This study analysed the association of monocyte chemoattractant protein-1 (MCP-1) with measures of vascular function in 477 patients with T2DM and 261 patients without T2DM. Endothelium-dependent and endothelium-independent microvascular responses were assessed by measuring vasodilator responses to iontophoresis of acetylcholine (ACh) and sodium nitroprusside (SNP), respectively, using laser Doppler imaging (LDI). Large artery stiffness was measured using carotid-femoral pulse wave velocity (cf-PWV). RESULTS: MCP-1 was inversely associated with ACh and SNP responses, in patients with and without T2DM. Each SD higher MCP-1 was associated with lower ACh (β = -21.7 AU, 95% CI: -34.3 to -9.0) and SNP (β = -20.5 AU, 95% CI: -32.5 to -8.4) responses after adjustment for CVD risk factors, BMI, HbA1c, eGFR, medication and study centre, with similar associations in patients with and without T2DM. MCP-1 was not associated with the ACh:SNP ratio or with cf-PWV, and the associations were not modified by BMI. CONCLUSION: This study shows MCP-1 to be associated with reduced microvascular vasodilator capacity, affecting endothelium-dependent and endothelium-independent responses, in patients with and without T2DM, independently of adiposity. Longitudinal studies in larger cohorts are required to determine whether MCP-1 improves CVD risk prediction and identifies patients most likely to benefit from targeted therapy.
No takes yet. Share an insight, caveat, or question.
MacDonald et al. (2026) conducted a cross-sectional in Type 2 diabetes mellitus and vascular function (n=738). Monocyte chemoattractant protein-1 (MCP-1) levels vs. Lower MCP-1 levels (per SD change) in patients with and without T2DM was evaluated on Endothelium-dependent (acetylcholine [ACh]) and endothelium-independent (sodium nitroprusside [SNP]) microvascular vasodilator responses and carotid-femoral pulse wave velocity (cf-PWV) (β -21.7 AU (ACh); β -20.5 AU (SNP) per SD higher MCP-1, 95% CI -34.3 to -9.0 (ACh); -32.5 to -8.4 (SNP)).
Synapse has enriched 10 related papers. Consider them for comparative context: